Welcome to our dedicated page for Nano-X Imaging Ltd. news (Ticker: NNOX), a resource for investors and traders seeking the latest updates and insights on Nano-X Imaging Ltd. stock.
NANO-X IMAGING LTD (Nanox) (NASDAQ: NNOX) is a medical imaging technology company that combines imaging hardware, AI-based software, cloud infrastructure, and teleradiology services. The Nanox news feed on this page aggregates company press releases and market updates so readers can follow how Nanox advances its imaging platform, commercial strategy, and capital markets activity over time.
Nanox’s recent news highlights its Nanox.ARC and Nanox.ARC X multi-source digital tomosynthesis systems, including CE Mark certification for Nanox.ARC in Europe and FDA 510(k) clearance for Nanox.ARC X for general use in multiple clinical indications. Articles also cover distribution agreements and collaborations with partners in countries such as France, the Czech Republic, Greece, Romania, Serbia, Montenegro, and Bosnia and Herzegovina, reflecting efforts to expand clinical and commercial deployment of its imaging solutions.
Another key news theme is the growth of Nanox.AI and its imaging analytics portfolio. Press releases describe AI algorithms that analyze routine CT scans for early signs associated with chronic diseases and bone health solutions such as HealthVCF and HealthOST, which have been included in an Early Value Assessment by the UK National Institute for Health and Care Excellence. Updates also discuss acquisitions like VasoHealthcare IT, intended to support deployment of AI solutions across U.S. healthcare facilities.
Investors and analysts can also find financial results announcements, guidance updates, and details of registered direct offerings and other financings, as reported in Nanox’s press releases and related SEC filings. Together, these news items provide insight into Nanox’s commercialization progress, clinical collaborations, AI development roadmap, and capital strategy. Bookmark this page to access an organized stream of Nanox news, from product and partnership updates to financial and regulatory disclosures.
Nanox has announced its Nanox.ARC digital x-ray technology received 510(k) clearance from the FDA, a crucial milestone on its regulatory path in the US. The company plans to start system shipments in late 2021 and aims to deploy 15,000 systems by 2024, expanding accessibility to medical imaging globally. They also intend to submit an additional 510(k) application for their multi-source system in 2021, which could further enhance their commercial offerings.
NANO-X IMAGING LTD (NASDAQ: NNOX) announces that CEO Ran Poliakine will present at the Oppenheimer 31st Annual Virtual Healthcare Conference from March 16-18, 2021. His presentation is scheduled for March 17 at 10:40am ET and will be available via a live webcast. Interested parties can access the presentation through the company’s website, with a replay available for 90 days afterward. Nanox aims to transform medical imaging with affordable solutions, promoting early detection through collaborations with leading healthcare organizations.
Nano-X Imaging Ltd (NASDAQ: NNOX) reported its fourth quarter 2020 results, highlighting the successful demonstration of its Nanox.ARC at the RSNA Virtual Annual Meeting. The company plans to initiate product shipments in Q4 2021. As of Q4 2020, it held $213 million in cash, with no debt. However, the company reported a net loss of $19 million for the quarter and $43.8 million for the year. R&D expenses increased significantly, from $2.7 million in 2019 to $9.2 million, reflecting ongoing development efforts. The company aims to deploy 15,000 Nanox.ARC units globally by 2024.
NANO-X IMAGING LTD (NASDAQ: NNOX) will announce its Q4 and full year 2020 financial results on March 2, 2021, prior to market opening. A conference call and webcast will follow at 8:30 AM ET. The company focuses on developing an innovative digital X-ray source for medical imaging, aiming to reduce costs and improve access to imaging services. The management's forward-looking statements highlight anticipated risks such as regulatory compliance, technological feasibility, and potential disruptions from public health issues.
NANO-X IMAGING LTD (NASDAQ: NNOX) announced the pricing of its underwritten public offering of 3,091,635 ordinary shares at $62.50 per share, expected to close around February 16, 2021. Notably, the company will not sell any shares nor receive proceeds from this offering, as it involves non-officer, non-director shareholders. Cantor Fitzgerald & Co. and Oppenheimer & Co. are the lead managers for the offering. The SEC has declared the necessary registration effective, with final prospectus copies available through specified channels.
Nano-X Imaging Ltd (NASDAQ: NNOX) announced a proposed underwritten public offering of 2,891,322 ordinary shares by non-officer, non-director shareholders. The company will not receive any proceeds from this sale. The offering is subject to market conditions and comes amid ongoing developments in Nano-X's innovative medical imaging technology. Cantor Fitzgerald & Co. and Oppenheimer & Co. are leading the offering, while a registration statement has been filed but not yet become effective. No assurances are made regarding the timing or completion of the sale.
Nanox Imaging (NNOX) has announced the appointment of three senior executives: Jim Dara as Chief Operating Officer, Ofir Koren as Chief Technology Officer, and Tamar Aharon as Chief Marketing Officer. These additions aim to drive the company's mission to democratize medical imaging. Nanox plans to begin deploying its Nanox.ARC technology in the latter half of 2021, pending regulatory approval. The leadership team is expected to provide diverse expertise, enhancing Nanox's capabilities in launching innovative medical imaging solutions.
NANO-X IMAGING LTD (NASDAQ: NNOX) announces participation in the Virtual 39th Annual J.P. Morgan Healthcare Conference from January 11-14, 2021. CEO Ran Poliakine will present on January 14 at 9:10 AM ET, available via live webcast. This event aims to showcase Nanox’s innovative medical imaging technology, designed to reduce costs and improve accessibility for healthcare services. Interested parties can access the webcast on Nanox’s website, with a replay available for 90 days post-event.
NANO-X IMAGING LTD (NASDAQ: NNOX) announced an extension of its collaboration with USARAD Holdings to launch a cutting-edge radiology diagnostics service. This service combines over 300 radiologists and 20 FDA-cleared AI algorithms, targeting key healthcare players in the U.S. The initiative follows a prior agreement to deploy 3,000 Nanox.ARC medical imaging systems. With a focus on urgent conditions and routine reviews, the program aims to enhance healthcare quality and affordability while prioritizing urgent cases through advanced algorithms.
NANO-X IMAGING LTD (NNOX) unveiled its next-generation x-ray prototype, Nanox.ARC, at the RSNA Virtual Annual Meeting. The demonstration showcased various 2D and 3D imaging procedures. CEO Ran Poliakine emphasized that the technology could provide medical imaging access to two-thirds of the global population lacking it. The company has secured agreements for over 5,100 Nanox.ARC units and aims to commence deployments as early as mid-2021, pending regulatory approvals. This innovation is expected to enhance preventive healthcare through early disease detection.